[{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"PCS499","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Processa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Processa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Aposense","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Irinotecan Hydrochloride","moa":"DNA Topoisomerase I","graph1":"Oncology","graph2":"Undisclosed","graph3":"Processa Pharmaceuticals","amount2":0.13,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"","sponsorNew":"Processa Pharmaceuticals \/ Aposense","highestDevelopmentStatusID":"1","companyTruncated":"Processa Pharmaceuticals \/ Aposense"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Processa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Eniluracil","moa":"DPD","graph1":"Oncology","graph2":"Phase I","graph3":"Processa Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Processa Pharmaceuticals \/ Processa Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Processa Pharmaceuticals \/ Processa Pharmaceuticals"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Eniluracil","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Processa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Processa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Eniluracil","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Processa Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Processa Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"6","companyTruncated":"Processa Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Processa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Processa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Eniluracil","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Processa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Processa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Eniluracil","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Processa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Processa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Eniluracil","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Processa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Processa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Irinotecan Hydrochloride","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Processa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Processa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Eniluracil","moa":"||DPD","graph1":"Oncology","graph2":"Phase II","graph3":"Processa Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Processa Pharmaceuticals \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Processa Pharmaceuticals \/ Alliance Global Partners"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Eniluracil","moa":"||DPD","graph1":"Oncology","graph2":"Phase II","graph3":"Processa Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Processa Pharmaceuticals \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Processa Pharmaceuticals \/ Alliance Global Partners"}]